[1]肖春芳.尿路感染患者奇异变形杆菌分布及耐药性分析[J].医学信息,2021,34(24):187-189.[doi:10.3969/j.issn.1006-1959.2021.24.051]
　XIAO Chun-fang.Distribution and Drug Resistance of Proteus Mirabilis in Patients with Urinary Tract Infection[J].Medical Information,2021,34(24):187-189.[doi:10.3969/j.issn.1006-1959.2021.24.051]
点击复制

尿路感染患者奇异变形杆菌分布及耐药性分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年24期
页码:
187-189
栏目:
诊疗技术
出版日期:
2021-12-15

文章信息/Info

Title:
Distribution and Drug Resistance of Proteus Mirabilis in Patients with Urinary Tract Infection
文章编号:
1006-1959（2021）24-0187-03
作者:
肖春芳
（崇义县人民医院医学检验科，江西 崇义 341300）
Author(s):
XIAO Chun-fang
(Department of Laboratory Medicine,Chongyi County People’s Hospital,Chongyi 341300,Jiangxi,China)
关键词:
尿路感染; 奇异变形杆菌; 耐药性
Keywords:
Urinary tract infection; Proteus mirabilis; Drug resistance
分类号:
R691.3
DOI:
10.3969/j.issn.1006-1959.2021.24.051
文献标志码:
A
摘要:
目的 研究尿路感染患者奇异变形杆菌分布特点和耐药性，为临床尿路感染患者的治疗提供可靠的参考依据。方法 选取2018年8月-2021年8月在我院诊治的80例尿路感染患者为研究对象，进行奇异变形杆菌检测，观察尿路感染患者奇异变形杆菌检出率、分布特点、耐药性。结果 80例尿路感染患者中，检出45株奇异变形杆菌，其中尿道口检出率42.22%，尿液检出率为31.11%，导尿管生物被膜中检出率为26.67%。奇异变形杆菌对氨苄西林耐药最高，其次为哌拉西林/他唑巴坦、庆大霉素、头孢噻肟和复方磺胺甲噁唑，对头孢他啶、亚胺培南、阿米卡星、美罗培南耐药率较低，均为20%以下，差异有统计学意义（P＜0.05），尿液、尿道口以及导尿管生物被膜抗生素敏感性比较，差异无统计学意义（P＞0.05）；ESBLs阴性菌对以上药物的耐药性均低于ESBLs阳性菌株。结论 尿路感染患者存在奇异变形杆菌，且主要分布于尿道口、尿液以及导尿管生物被膜中。不同抗生素耐药性不同，但是不同部位分离出的奇异变形杆菌对抗生素敏感性基本相似，ESBLs是形成奇异变形杆菌耐药的主要原因。临床对尿路感染患者应加强对ESBLs的检测，合理使用抗菌药物，在减少抗生素滥用现象的同时，提高尿路感染治疗疗效。
Abstract:
Objective To study the distribution characteristics and drug resistance of Proteus mirabilis in patients with urinary tract infection, and to provide reliable reference for the treatment of patients with urinary tract infection.Methods A total of 80 patients with urinary tract infection diagnosed and treated in our hospital from August 2018 to August 2021 were selected as the research objects. All patients were detected Proteus mirabilis, the detection rate, distribution characteristics and drug resistance in patients with urinary tract infection were observed.Results Among 80 patients with urinary tract infection, 45 strains of Proteus mirabilis were detected, among which the detection rate of urinary tract entrance was 42.22%, the detection rate of urine was 31.11%, and the detection rate of catheter biofilm was 26.67%. The resistance of Proteus mirabilis to ampicillin was the highest, followed by piperacillin/tazobactam, gentamicin, cefotaxime and compound sulfamethoxazole, and the resistance rates to ceftazidime, imipenem, amikacin and meropenem were all lower than 20%, with statistically significant differences (P<0.05). There was no significant difference in the sensitivity of urine, urinary tract orifice and catheter biofilm antibiotics (P>0.05). The resistance of ESBLs-negative bacteria to the above drugs was lower than that of ESBLs-positive strains.Conclusion There are Proteus mirabilis in patients with urinary tract infection, which is mainly distributed in the urinary tract entrance, urine and catheter biofilm. Different antibiotic resistance is different, but the sensitivity of Proteus mirabilis isolated from different parts to antibiotics is basically similar, ESBLs is the main reason for the formation of Proteus mirabilis resistance. Clinical detection of ESBLs should be strengthened in patients with urinary tract infection.Rational use of antibiotics can reduce the abuse of antibiotics and improve the therapeutic effect of urinary tract infection.

参考文献/References:

[1]袁朝勇,何涛,黄文杰,等.老年患者医院下尿路感染的易感因素与治疗策略分析[J].中华医院感染学杂志,2017,27(21):4902-4904,4967.[2]王爱红.泌尿科患者多重耐药菌感染情况分析[J].贵州医药,2016,40(1):62-63.[3]朱冬菊.攀枝花地区老年患者肠球菌尿路感染的细菌分布及耐药性分析[J].现代预防医学,2018,45(18):3386-3388,3400.[4]姚金元,杨一鸣,顾蓓青,等.135株奇异变形杆菌的标本分布及耐药性分析[J].中国消毒学杂志,2016,33(3):289-290.[5]丁厚文,刘周,吴园园,等.1127株尿培养病原菌分布及耐药性分析[J].国际检验医学杂志,2018,9(4):477-480.[6]Melo LDR,Patrícia V,Nuno C,et al.Development of aPhage Cocktail to Control Proteus mirabilis Catheter-as sociated Urinary Tract Infections[J].Front Microbiol,2016,7(1024):1-12.[7]王云娟,宋贵波,苏艳丹,等.2013-2015年云南省三级医院尿培养病原菌分布及耐药性分析[J].中国抗生素杂志,2017,42(7):548-560.[8]吴风华,钟景虹.泌尿系统感染病原菌检验及检验常见菌耐药性分析[J].中国医药科学,2018,8(5):152-154.[9]洪金玲,李维正,周璇,等.尿路致病性大肠埃希菌多位点序列分型与耐药谱型的相关性[J].中华实验和临床感染病杂志,2018,12(2):155-159.[10]张元媛,张国斌,徐丽.下尿路感染患者尿液病原菌分布及其耐药性分析[J].海军医学杂志,2017,38(6):521-523.[11]张利霞,胡同平,王占黎,等.2014-2017年某医院152例尿路感染肠球菌耐药性监测分析[J].中国医院药学杂志,2018,38(22):2368-2372.[12]刘代华,李俊明,覃禹,等.成人住院患者尿路感染及经验用药调查[J].中国医院药学杂志,2018,38(19):2054-2057.[13]孙涛,贾洪涛,王秀新,等.复杂性尿路感染的病原菌分布及革兰阴性杆菌的耐药性分析[J].国际泌尿系统杂志,2018,38(2):237-240.[14]杰文红.复发性尿路感染的细菌检验和药敏情况及治疗研究[J].中国医药指南,2018,16(3):106.[15]杜震,乔庐东,闫伟,等.导管相关尿路感染患者尿路上皮细胞内检出细菌群落的临床意义[J].中华泌尿外科杂志,2017,38(1):51-54.[16]刘丹,黄婷婷,王哲,等.老年与中青年病人产ESBLs大肠埃希菌的分布及耐药性对比分析[J].实用老年医学,2017,7(1):61-64.[17]韦月玉,许振培,劳世晖,等.老年糖尿病肾病留置尿管患者尿路感染病原菌及耐药性分析[J].中华医院感染学杂志,2018,28(17):2596-2598,2720.[18]谢朝云,熊芸,孙静,等.泌尿外科导尿管与非导尿管相关性尿路感染病原菌分布及耐药性比较[J].中国现代医学杂志,2018,28(1):61-66.[18]杨仁国,王蜀强,龙姗姗,等.复杂性尿路感染243例病原菌构成及药敏分析[J].中国抗菌药物杂志,2017,42(12):1050-1055.[19]王双凤,刘会范,左书强,等.输尿管皮肤造口患者尿路感染的危险因素分析及预防对策[J].中国消毒学杂志,2018,35(11):853-855.[20]黄兴,董亮,张秀红,等.无锡市某医院老年女性10042份尿培养标本病原菌分布及耐药性分析[J].现代预防医学,2018,45(17):3182-3185.

相似文献/References:

[1]柳 梅.头孢哌酮钠舒巴坦钠治疗糖尿病并发尿路感染的 临床效果观察[J].医学信息,2018,31(07):139.[doi:10.3969/j.issn.1006-1959.2018.07.047]
　LIU Mei.Clinical Efficacy of Cefoperazone Sodium and Sulbactam Sodium in Treatment of Diabetes Complicated with Urinary Tract Infection[J].Medical Information,2018,31(24):139.[doi:10.3969/j.issn.1006-1959.2018.07.047]
[2]雷 欣,陈筱云.糖尿病合并尿路感染中医临证治验[J].医学信息,2021,34(07):162.[doi:10.3969/j.issn.1006-1959.2021.07.046]
[3]茹银转,胡桂贞,陈云开,等.2018年~2020年某基层医院尿路感染的细菌分布及耐药状况调查[J].医学信息,2021,34(12):148.[doi:10.3969/j.issn.1006-1959.2021.12.040]
　RU Yin-zhuan,HU Gui-zhen,CHEN Yun-kai,et al.Survey of Bacterial Distribution and Drug Resistance of Urinary Tract Infections in a Primary Hospital from 2018 to 2020[J].Medical Information,2021,34(24):148.[doi:10.3969/j.issn.1006-1959.2021.12.040]
[4]魏长斌.头孢哌酮钠舒巴坦钠对糖尿病合并尿路感染的疗效及安全性分析[J].医学信息,2021,34(14):151.[doi:10.3969/j.issn.1006-1959.2021.14.042]
　WEI Chang-bin.Analysis of the Efficacy and Safety of Cefoperazone Sodium and Sulbactam Sodium on Diabetes Complicated with Urinary Tract Infection[J].Medical Information,2021,34(24):151.[doi:10.3969/j.issn.1006-1959.2021.14.042]
[5]钱菲菲,周 易.尿路感染诊断治疗中临床微生物检验的病原菌结果分析[J].医学信息,2022,35(23):159.[doi:10.3969/j.issn.1006-1959.2022.23.035]
　QIAN Fei-fei,ZHOU Yi.Analysis of Pathogenic Bacteria Results of Clinical Microbiological Examination in the Diagnosis and Treatment of Urinary Tract Infection[J].Medical Information,2022,35(24):159.[doi:10.3969/j.issn.1006-1959.2022.23.035]
[6]邹 莉,邹长娇,陈丽华.新型泌尿外科护理管理模式对外科住院患者治疗及降低院内尿路感染的影响[J].医学信息,2024,37(05):161.[doi:10.3969/j.issn.1006-1959.2024.05.030]
　ZOU Li,ZOU Chang-jiao,CHEN Li-hua.Effect of New Urological Nursing Management Model on the Treatment and the Reduction of Nosocomial Urinary Tract Infection for Surgical Inpatients[J].Medical Information,2024,37(24):161.[doi:10.3969/j.issn.1006-1959.2024.05.030]

更新日期/Last Update: 1900-01-01